BlackRock Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

BlackRock Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$754K	Buy	40,017 +2,484	+7%	+$60.8K	﹤0.01%	1985
2016 Q3	$1.13M	Buy	37,533 +1,307	+4%	+$40.7K	﹤0.01%	1764
2016 Q2	$1.39M	Buy	36,226 +21,199	+141%	+$880K	﹤0.01%	1618
2016 Q1	$572K	Buy	15,027 +908	+6%	+$31.6K	﹤0.01%	2010
2015 Q4	$621K	Buy	14,119 +3,573	+34%	+$177K	﹤0.01%	1975
2015 Q3	$429K	Buy	10,546 +7,016	+199%	+$308K	﹤0.01%	2292
2015 Q2	$188K	Hold	3,530	–	–	﹤0.01%	2829
2015 Q1	$214K	Sell	3,530 -124,970	-97%	-$6.06M	﹤0.01%	2636
2014 Q4	$6.71M	Buy	+128,500	New	+$5.75M	0.01%	888

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's JUNO Position: Q4 2016 in Review

BlackRock Advisors increased its Juno Therapeutics, Inc. (JUNO) stake by 6.6% in Q4 2016, buying an estimated $60.8K and bringing the position to 40,017 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #1985.

BlackRock Advisors first reported a position in JUNO in Q4 2014 and has held it in 9 quarters since. The position peaked at $6.71M in Q4 2014. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

BlackRock Advisors held 40,017 shares of Juno Therapeutics, Inc. worth $754K as of Q4 2016.
BlackRock Advisors bought 2,484 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $60.8K.
Juno Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1985 holding.
BlackRock Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's Juno Therapeutics, Inc. position peaked at $6.71M in Q4 2014.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.